Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Vetter Receives “Known Consignor” Approval from Germany's Federal Aviation Office

Published: Wednesday, December 12, 2012
Last Updated: Wednesday, December 12, 2012
Bookmark and Share
The CDMO meets new requirements six months ahead of deadline.

Vetter has announced that it has now been approved as a “Known Consignor” by the German Federal Aviation Office. The agency officially granted the pharmaceutical service provider the certificate of approval following an audit at Vetter´s Holbeinstrasse and Ravensburg Vetter West facilities.

The approval means that customers will continue to have their air cargo products loaded, transported and delivered quickly and safely, saving valuable time and money.

Vetter had already been designated as a “Known Consignor” back in 2006. The goal of the certification is primarily to provide more security for air cargo.

Until recently, logistics companies themselves issued the certificate. New EU regulations concerning the so-called "safe supply chains" require that companies must now have their status audited and approved by the Federal Aviation Office.

The criteria for certification are extensive and include elaborating a safety concept, training personnel, and the assurance that the shipping of freight is performed in a way that cannot be tampered with.

Any attempt to open the shipment would be immediately evident. The Federal Aviation Office grants the certificate for five years and carries out unannounced controls on a regular basis.

"Our approval as a "Known Consignor" allows our customers fast and smooth loading of air freight packages at the airport, including a high level of security,” said managing director Thomas Otto.

Otto continued, “Once time-consuming x-rays and searches are no longer necessary, saving invaluable effort and cost. For Vetter, the status of ”Known Consignor” is further proof of the high product quality that we offer our customers.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vetter Announces Office Opening in Japan
Company’s second office in the region will strengthen customer relations and help develop new business among emerging and established Japanese companies.
Thursday, October 15, 2015
Vetter Embarks on a 300 Million Euro Investment Strategy
Company will invest for further development to its manufacturing sites and to make available additional manufacturing capacities.
Thursday, October 01, 2015
Vetter Development Service Chicago Completes Recent On-Site Expansion Activities
Continued demand and increased customer product transfers are generating a positive business outlook for the company’s early-stage development facility.
Thursday, June 11, 2015
Vetter Serializes the First Product for South Korea
CDMO produces clearly identifiable labelling for a top-ten pharmaceutical company.
Saturday, May 02, 2015
Vetter Appoints Oliver Albrecht as Managing Director
Role with company commenced on April 1, 2015.
Thursday, April 09, 2015
Vetter Continues to Expand Capacity
Structural work completed on Vetter’s new multi-functional building for its Development Service and information technology (IT).
Friday, January 30, 2015
Vetter Adds Flexible Serialization Service to its Portfolio
A new service allowing for the explicit identification of drug packaging.
Thursday, December 04, 2014
Vetter Announces Opening of Office to Support Growing Asian Healthcare Market
New Asia Pacific office will support customer relations and the development of new business.
Friday, November 21, 2014
Vetter Announces Personnel Changes in its Development Service Division
Clinical manufacturing services continue to attract new business.
Saturday, October 18, 2014
Vetter Continues to Strengthen its Market Position
Another positive year for the CDMO.
Wednesday, January 15, 2014
Vetter to Construct New Filling Lines to Expand Capacity
Responding to customer demand and company growth.
Thursday, October 10, 2013
Vetter’s Newest Facility Successfully Completes FDA Inspection
Center for visual inspection and logistics sets high safety and control standards.
Thursday, March 28, 2013
Vetter Receives Top Prize at the European Outsourcing Awards Ceremony
CDMO clinches an industry Oscar for its innovative high-speed filling line.
Friday, October 12, 2012
Vetter’s Development Service Doubles its Revenues and Grows its Capabilities
Ravensburg development labs add enhanced technologies.
Friday, September 28, 2012
Vetter Prepares for Further Growth
A leading CDMO secures triple-digit million euro credit facility.
Tuesday, May 01, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos